Universal enzymatic DNA and RNA removal for molecular testing samples and kits
A novel enzyme-based solution that eliminates background nucleic acids from molecular diagnostic reagents and samples, improving sensitivity, specificity, and reproducibility. Produced in a non-bacterial host to avoid contamination, the approach works at room temperature in 10–15 minutes and adapts to low or high-throughput workflows.
Overview
Molecular diagnostic and research tests depend on clean samples and reagents. Background nucleic acids—free DNA and RNA present in kits or specimens—can cause false positives or negatives, undermining the reliability of genetic analysis. Medix Bio is developing a universal enzymatic solution that removes background DNA and RNA from both samples and diagnostic kits. By producing the enzymes in a non-bacterial host, the technology eliminates the risk of introducing contaminating bacterial nucleic acids into testing workflows. The result is improved sensitivity and specificity, more reproducible data, and streamlined laboratory operations across clinical diagnostics, food testing, research, and pharmaceutical R&D.
Technical specifications
Key features:
- A set of DNA-digesting enzymes produced in a non-bacterial host, eliminating bacterial DNA contamination in the preparation itself
- Universal enzymatic removal of background DNA and RNA from samples and kit reagents
- Compatible with amplification enzymes such as Taq DNA polymerase and other polymerases across different kit formats
- Room-temperature treatment requiring approximately 10 to 15 minutes
- Adaptable for both low-throughput and high-throughput workflows
- Enhanced sensitivity and specificity by reducing false positives and false negatives
- Consistent and reproducible results through standardized elimination of free nucleic acids
The approach builds on prior experience launching DNA-free Taq polymerase to market and extends the concept beyond a single enzyme to a universal, broadly applicable removal system.
Technology readiness level
The underlying concept has prior commercial validation through the launch of bacterial-DNA-free Taq DNA polymerase at a previous company. Medix Bio's new universal enzymatic DNA removal kit is in the development and validation stage, with future validation planned to confirm enhanced sensitivity and specificity, reproducibility across food testing, research, and clinical trial settings, and compatibility with high-throughput laboratory environments.
About Medixbio Inc
Medix Biotechnologies Inc. develops AI-enabled molecular diagnostic solutions designed to provide laboratory-grade testing accuracy in point-of-care and home settings. At the core of its product ecosystem is Genometriq™, an algorithmic design engine that utilizes advanced computational methods and artificial neural networks to automate the development of highly specific, multiplexed molecular assays. These assays are designed to detect multiple pathogens and antibiotic resistance genes simultaneously, with platforms such as Hypersens™, Ultrasens™, and Rapidmarc™ facilitating rapid testing across various formats, from smartphone-read self-test cards to qPCR kits.
By streamlining the identification of genetic targets and enabling rapid, decentralized testing, Medix aims to address fragmented and inefficient diagnostic pathways. The company's platforms, often complemented by TreatOnce™ clinical decision support software, assist clinicians and researchers by mapping detected pathogens to targeted antimicrobial treatment options. These tools are intended to improve testing efficiency, reduce turnaround times, and support informed treatment decisions in fields including infectious diseases, pharmaceutical R&D, and food safety, with many of its current offerings provided for research use only.
delivered to your inbox.